Rowan Gardner is a life science strategy and business development professional with a substantial network of investor contacts that participate in all stages of company creation and growth. As Head of Investor Relations at Oxford Molecular she developed and delivered the corporate communications, IR and PR strategies.
Rowan maintains close relationships with various industry groups such as Astia, and Digital Health Forum. She has consulted to various UK RDAs, SMEs and financial institutions to help broker, fund and develop new initiatives. Rowan has recently led projects to bring new venture and translational capital into the UK life sciences sector.
Dr Steve Gardner has over 20 years of experience and a strong track record of building world-class companies, teams and products within the life science and healthcare industries. He specializes in designing and delivering advanced semantic integration and search systems and has raised over £50M, participated in an LSE flotation and 11 corporate acquisitions. In his role as CTO of BioWisdom he worked on over 25 safety, regulatory and marketing projects for major pharmaceutical companies and provided the informatics support to the InnoMed (Alzheimer’s biomarkers) project for the EU under the FP6 programme. Steve was a lead contributor to the €2B EU IMI programme’s Strategic Research Agenda. Steve was founder and CEO of Synomics Ltd and European MD and CTO for Viaken Systems. Prior to that, Steve was Worldwide Director of Research Informatics for Astra AB, and as Senior Product Manager at Oxford Molecular, he co‐ordinated the senior scientific advisory meetings including four Nobel Laureates..